Table 12.

In vitro cytotoxic activity [IC₅₀ (μM)^a] of compounds (19a-j) [54]

Compound	Lung cancerA549c	Breast cancer
		MCF-7b	MDA MB-231d
19a	9.78 ± 0.27	34.55 ± 2.34	–
19b	0.45 ± 0.03	1.76 ± 0.34	2.11 ± 0.21
19c	3.67 ± 0.18	2.89 ± 0.67	12.76 ± 0.81
19d	4.56 ± 0.19	2.33 ± 0.56	7.34 ± 0.26
19e	13.78 ± 1.78	12.4 ± 0.79	19.5 ± 2.11
19f	34.9 ± 2.30	15.3 ± 1.72	–
19g	1.03 ± 0.17	1.23 ± 0.30	1.89 ± 0.35
19h	2.45 ± 0.23	0.34 ± 0.025	1.11 ± 0.18
19i	1.89 ± 0.38	1.90 ± 0.41	3.78 ± 0.29
19j	87.5 ± 4.67	6.30 ± 0.35	22.5 ± 1.28
Doxorubicin	2.10 ± 0.14	3.12 ± 0.17	3.41 ± 0.23

(–) not active, ^aEach data represents as mean ± S.D values. From three different experiments performed in triplicates. MCF-7: Human breast cancer cell line. ^cA549: Human lung cancer cell line. MDA MB-231^d: Human breast cancer cell line